Illumina to Present at the 25th Annual JP Morgan Healthcare Conference

Business Wire, Dec 22, 2006

SAN DIEGO -- Illumina, Inc. (NASDAQ:ILMN) announced today that Jay Flatley, President and Chief Executive Officer, will present an overview of the Company's commercial and product development activity at the upcoming JP Morgan Healthcare Conference in San Francisco, California.

Mr. Flatley's presentation will be webcast at 9:00 a.m. Pacific Standard Time (PST) on Wednesday, January 10, 2007. The following URL provides direct access to the live presentation as well as an archived file following the event: https://events.jpmorgan.com.

About Illumina

Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, the Company's ability to scale and integrate technology acquired from CyVera, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix([R]) arrays -- including HumanHap BeadChips -- and Oligator([R]) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.